• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Top 5 Most-Read Atopic Dermatitis Articles of 2022


This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.

The association between atopic dermatitis (AD) and other diseases, job types, and sleep and attention issues were investigated in the top 5 most-read AD articles published on AJMC.com.

Here are the top 5 most-read AD articles of 2022.

5. Risk of Dementia Elevated in Patients With Atopic Dermatitis

An increased risk of incident dementia was observed among patients with AD compared with the general population, in which those with more severe disease were at greatest risk. Study findings examining United Kingdom electronic health record data indicated that patients with AD were 27% more likely to have dementia (HR, 1.27; 95% CI, 1.23-1.30), with an Incidence rate of 57 per 10,000 person-years among those with AD (12.1% of the population) vs 44 per 10,000 person-years in the control group.

Read the full article here.

4. Jobs in Forestry, Agriculture Linked With Increased AD Risk in Workers' Children

An analysis utilizing data from the Japan Environment and Children’s Study project showed that Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, were at greater risk of AD development. Findings contradicted the hygiene hypothesis, which assumes a low incidence of allergic diseases in families engaging in farming work. Among the 3 primary industries noted, forestry was associated with the highest incidence of AD at 6 months of age, 1 year, 2 years, and 3 years.

Read the full article here.

3. Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD

A shared evaluative approach between allergy, immunology, and dermatology specialists in a multidisciplinary integrated clinic (MDIC) was found to identify additional comorbid conditions among patients with severe AD. Findings presented at the 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting showed that the MDIC model of evaluating patients with AD successfully identified patients with additional contact dermatitis, atopy, or immune dysfunction that contributed to more severe AD.

Read the full article here.

2. AD Severity Linked With Sleep, Attention Issues in Young Children

Findings of a study showed a significantly increased risk of sleep health and attention regulation issues among children with moderate to severe AD. Compared with children who have mild disease, poor sleep resulted in significant mood impairment in those with moderate to severe AD, with 36% having trouble getting along with other children and 68% crying easily because of poor sleep. Moreover, 80% of children with severe AD reported issues in sitting still and 72% cited trouble paying attention no matter their surroundings.

Read the full article here.

1. Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis

A study examining longer-term use of the Janus kinase (JAK) inhibitor upadacitinib showed sustained efficacy in the treatment of moderate to severe AD after 52 weeks, with a favorable benefit-risk profile exhibited among adult and adolescent patients. The Measure Up 1 and 2 studies, which informed the FDA approval of upadacitinib for the treatment of moderate to severe AD in adults and adolescents 12 years and older, will continue to examine patients through 260 weeks, the researchers noted, at which point longer-term data will be valuable for evaluating the efficacy and safety of the JAK inhibitor for the chronic disease.

Read the full article here.

Related Videos
dr april armstrong
dr peter lio
dr april armstrong
dr april armstrong
dr april armstrong
Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre
Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences
Andy Blauvelt, MD, MBA, president, Oregon Medical Research Center
Related Content
© 2023 MJH Life Sciences
All rights reserved.